Aldeyra Therapeutics, Inc.
ALDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001341235
No open-market purchases or sales by Aldeyra Therapeutics, Inc. insiders were filed in the last 90 days; 107 institutions reported holding it in 13F filings for Q2 2026, worth $78.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −19 vs. previous quarter
- 107
- 13F valueReported value at the end of Q2 2026
- $78.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ALDX, Q2 2026
No superinvestor reported holding ALDX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Aldeyra Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Brady Todd CPresident and CEO | PPurchase | +250.0K | $1.67 | +$417.5K | +17.0%1.72M after | |
| Mar 20, 2026 (view filing) | Mar 19 | 1 day | Douglas RichardDirector | PPurchase | +70.0K | $1.40 | +$98.0K | +56.0%195.0K after | |
| Mar 19, 2026 (view filing) | Mar 18 | 1 day | Alfieri MichaelPrincipal Financial Officer | PPurchase | +5.00K | $1.42 | +$7.10K | +200.0%7.50K after | |
| Aug 15, 2025 (view filing) | Aug 13 | 2 days | Alfieri MichaelPrincipal Financial Officer | PPurchase | +2.50K | $5.30 | +$13.3K | New position2.50K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | Machatha StephenChief Development Officer | SSale | −22.1K | $5.15 | −$113.7K | −9.1%221.8K after | |
| Apr 7, 2025 (view filing)6:43 PM ET | Apr 3 | 4 days | Edelman Joseph and 2 others10% Owner | SSale | −3.40M | $1.42 | −$4.83M | −36.7%5.88M after | |
| Oct 21, 2024 (view filing) | May 3, 2021-Apr 12, 2023 | 1,267 daysLate | Miller-Rich NancyDirector | PPurchase | +922 | $11.33 | +$10.4K | New position922 after | 2 lots |
| Aug 14, 2024 (view filing) | Aug 12 | 2 days | Machatha StephenChief Development Officer | SSale | −16.0K | $4.74 | −$76.0K | −6.3%236.8K after | |
| Aug 14, 2024 (view filing) | Aug 12 | 2 days | Greenberg BruceSee Remarks | SSale | −10.8K | $4.74 | −$51.4K | −7.9%126.4K after | |
| Apr 17, 2024 (view filing) | Mar 12 | 36 days | Machatha StephenChief Development Officer | SSale | −11.5K | $3.16 | −$36.5K | −4.4%252.8K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aldeyra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | $11.7M | 5.44% | 00.0% | Unchanged |
| AQR Capital Management LLC | 3,751,558 | $7.99M | 0.00% | +921,683+32.6% | Added |
| Kingdon Capital Management, L.L.C. | 2,652,315 | $5.65M | 0.76% | +500,000+23.2% | Added |
| Vanguard Capital Management LLC | 2,361,796 | $5.03M | 0.00% | −1,946−0.1% | Reduced |
| D. E. Shaw & Co., Inc. | 1,940,338 | $4.13M | 0.00% | +536,348+38.2% | Added |
| Marshall Wace, LLP | 1,506,974 | $3.21M | 0.00% | +1,377,281+1,062.0% | Added |
| 683 Capital Management, LLC | 1,450,000 | $3.09M | 0.28% | −50,000−3.3% | Reduced |
| Jane Street Group, LLC | 1,375,115 | $2.93M | 0.00% | +406,224+41.9% | Added |
| BlackRock, Inc. | 1,257,243 | $2.68M | 0.00% | −2,506,644−66.6% | Reduced |
| Qube Research & Technologies Ltd | 1,128,803 | $2.40M | 0.00% | +1,041,725+1,196.3% | Added |